초록 ▼

1. 적혈구배양 과정을 위한 최적의 배지개발을 위한 적혈구 분화, 탈핵화, 생산, 보존 기술 확립.
2. 배아줄기세포로부터 유래된 혈액/혈관 전구세포를 거쳐 조혈모세포로의 분화 및 증폭에 관련된 유전인자 및 촉진 물질발굴로 적혈구로 분화할 수 있는 전구세포의 효율적 확보.
3. 제대혈로부터 적혈구 전구세포로의 분화율을 높이는 유전인자 및 촉진 물질 발굴.
4. 적혈구 생성과정(Erythropoiesis)의 미세조혈환경(in vivo micro-environment)의 구현을 위해 생체재료를 활용함으로서 최적의 재질

1. 적혈구배양 과정을 위한 최적의 배지개발을 위한 적혈구 분화, 탈핵화, 생산, 보존 기술 확립.
2. 배아줄기세포로부터 유래된 혈액/혈관 전구세포를 거쳐 조혈모세포로의 분화 및 증폭에 관련된 유전인자 및 촉진 물질발굴로 적혈구로 분화할 수 있는 전구세포의 효율적 확보.
3. 제대혈로부터 적혈구 전구세포로의 분화율을 높이는 유전인자 및 촉진 물질 발굴.
4. 적혈구 생성과정(Erythropoiesis)의 미세조혈환경(in vivo micro-environment)의 구현을 위해 생체재료를 활용함으로서 최적의 재질 및 물리화학적 환경을 조성하여 검사실(in vitro)에서 조혈과정을 구현.
5. 적혈구의 생존연장 연구를 위한 배양환경 연구.
6. RhD 양성 혈액형을 RhD 음성 만능공혈 혈액 제작을 위한 혈액형 변환 기술 성공의 연구성과를 이루었으며, 대량생산이 가능한 세포치료제제로서 줄기세포 공정 시스템 기반 기술을 제공하여 줄기세포 기반 적혈구 대량생산을 위해 산업화에 필요한 모든원천기술을 확립하였음.

Abstract ▼

1. Purpose
Throughout the world, a precipitous blood product shortage is anticipated over the next 30 years. This is due to the decreasing transfusion donor population and the emergence of new transfusion related pathogens in the face of growing elderly populations. In the 1980s to 1990s, artific

1. Purpose
Throughout the world, a precipitous blood product shortage is anticipated over the next 30 years. This is due to the decreasing transfusion donor population and the emergence of new transfusion related pathogens in the face of growing elderly populations. In the 1980s to 1990s, artificial blood, using free hemoglobin solutions and perfluorocarbon as hemoglobin carriers, was proposed as possible solutions. However, these studies were terminated prematurely due to significant toxicity related adverse reactions in clinical trials. Then in 2005, researchers in France began efforts to amplify red blood cell production from human stem cells. This is a complex endeavor, as amplification of blood cells requires very specific and high level technical skills, a large research and development staff, as well as strict standards in quality control. Adding to these difficulties, competition among labs precluded effective international collaboration. Despite the challenges, we believe that the blood product shortage is a problem that must be addressed within our nation and that blood amplification is the key to resolve. Therefore, in 2010, we studied RBC production and amplification and report our successful findings.
2. Results
2-1. Success in the world's first attempts at in vitro RBC production methods using only human cells
2-2. Effective hematopoietic stem cells differentiation into mature RBCs and its ability to undergo oxygen dissociation
2-3. Replication of the bone marrow's internal milieu, in which RBCs undergo successful differentiation and proliferation.In vitro RBC amplification is able to be stored in refrigeration for one month.
2-4. Using DNA scissors to convert stem cell derived cell lines from D+ to D- RH types for the first time
2-5. In regards to “ In vitro erythroid cells methods in production," Korea license registration 10 times, application 5 times. PCT license registration 1 time, application 1 time, USA application 1 time
2-6. Related medical publications 6 times in SCI journal
3. Plans for research applications
3-1. Using bioreactors for amplification of RBCs derived from stem cells using above methods
3-2. Solution for transfusion transmitted infection derived blood product shortage
3-3. Contribution to the world's investment in developing technology for blood donation alternatives
3-4. Through the hematopoiesis model, better understanding pathologic mechanisms of hematologic disease processes
3-5. Methods to control blood typing and production of large quantities of blood for rare blood types